Clinical trial design issues raised during recombinant DNA advisory committee review of gene transfer protocols.
Gene transfer clinical trial protocols are reviewed by the Recombinant DNA Advisory Committee (RAC). Identifying the design concerns and suggestions commonly raised during RAC review may help investigators and sponsors shorten the process of protocol development and improve the quality of gene transfer trials. We therefore examined 53 full public reviews of gene transfer clinical trial protocols performed by the RAC between December 2000 and June 2004 to determine what trial design concerns or suggestions RAC members raised during written review or public discussion or in the formal letter to investigators after the review was completed. We also determined how frequently these concerns were raised. We found that RAC members raised issues regarding selection of subjects in 89% of reviews, dose escalation in 77%, selection of safety end points in 76%, biological activity measures in 66%, and overall design in 60% of reviews. The most common issue raised by RAC reviewers was the need to exclude subjects at increased risk for adverse events. Furthermore, in 89% of reviews, at least one design issue pertaining to safety of participants was raised. In 91% of reviews, at least one design concern was presented as a written RAC recommendation or concern to the investigator after the public review. When submitting protocols for RAC review, investigators and sponsors might devote more attention to issues that RAC reviewers commonly raise. Such attention might help strengthen clinical trial protocols, shorten the protocol development process, and enhance the protection of research participants.
Scharschmidt
Tiffany
T
School of Medicine and Program in Medical Ethics, and Division of General Internal Medicine, University of California San Francisco, San Francisco, CA 94143-0903, USA.
Lo
Bernard
B
D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000941:ethics / Q000592:standards; D028744:Ethics Committees, Research; D018014:Gene Transfer Techniques / Q000941:ethics / Q000592:standards; D015316:Genetic Therapy / Q000941:ethics / Q000592:standards; D033161:Government Regulation; D006801:Humans; D015201:Meta-Analysis as Topic; D009316:National Institutes of Health (U.S.); D014481:United States; D014486:United States Food and Drug Administration